Viking Therapeutics, Inc (VKTX) Stock Price

VKTXStock
$34.17+27.81%52W
Market Cap$3.99B
P/E
PEG Ratio
Div yield
Beta0.61

VKTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-1.03%
Price vs S&P 500 (4W)-4.91%
VGM Score59.22

VKTX Earnings Surprise History

Q2 25-0.58est. -0.44
Q3 25-0.81est. -0.67
Q4 25-1.38est. -0.90
Q1 26-1.37est. -0.91
Q2 26-1.10est. -1.21

VKTX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.24
4.23
4.23
4.23

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
VKTXViking Therapeutics, Inc
C$34.17
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Viking Therapeutics, Inc

Viking Therapeutics is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. Its clinical pipeline includes VK2809 and VK0214, oral selective thyroid hormone receptor beta agonists, and VK5211, an oral selective androgen receptor modulator, each targeting unmet medical needs in hormonal conditions.